Share Name Share Symbol Market Type Share ISIN Share Description
4d Pharma Plc LSE:DDDD London Ordinary Share GB00BJL5BR07 ORD 0.25P
  Price Change % Change Share Price Shares Traded Last Trade
  -4.00 -2.56% 152.00 2,085,755 16:35:01
Bid Price Offer Price High Price Low Price Open Price
153.00 154.50 165.50 153.00 156.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -29.43 -36.75 200
Last Trade Time Trade Type Trade Size Trade Price Currency
17:17:01 O 1,070 152.008 GBX

4d Pharma (DDDD) Latest News

More 4d Pharma News
4d Pharma Takeover Rumours

4d Pharma (DDDD) Discussions and Chat

4d Pharma Forums and Chat

Date Time Title Posts
01/10/202023:354D Pharma 2018 - from Ј2 back up to Ј10+10,522
20/9/202022:084d Pharma204
08/3/202021:164D Pharma (DDDD) One to Watch 8

Add a New Thread

4d Pharma (DDDD) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2020-10-01 16:17:02152.011,0701,626.49O
2020-10-01 16:06:26152.005,0007,600.00O
2020-10-01 15:35:01152.005,2637,999.76UT
2020-10-01 15:29:43153.008411,286.73AT
2020-10-01 15:29:33154.506,79010,490.55O
View all 4d Pharma trades in real-time

4d Pharma (DDDD) Top Chat Posts

4d Pharma Daily Update: 4d Pharma Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker DDDD. The last closing price for 4d Pharma was 156p.
4d Pharma Plc has a 4 week average price of 107.50p and a 12 week average price of 35.60p.
The 1 year high share price is 180p while the 1 year low share price is currently 23.50p.
There are currently 131,392,242 shares in issue and the average daily traded volume is 3,148,847 shares. The market capitalisation of 4d Pharma Plc is £199,716,207.84.
thepaddedcell: The Tesla effect perhaps ? They have seen a 100 fold increase in share price but over several years. Yanks like their cars too but also pharma companies, we just need the word to get out to a larger audience ! Nobody is knocking DDDD share price increases at the moment, just wait to see the reaction on the IBS trial results !
sportbilly1976: 19th - agree with your comments :) Purely technical on share price, resistances I can spot on a weekly candlestick chart are: 190-195p, 245-250p, 385-390p and then given the fall in share price during spring 2017 the next one at 670-675p
19th hole: With feet firmly on the ground, I'll refer people to the content of my post this morning. In 4/2016 the market cap of DDDD was £648M and the share price was £10. In round numbers the share price only has to rise to £5 to gain the equivalent m/cap today. I fully expect this to be hit. For the share price to be north of £10 we are looking at a m/cap of nearly £1.4B. Comparing share prices across the years in my view is pointless as it does not allow for dilution (which after all is what AIM is all about). M/cap comparison is far more worthwhile and a better indicator of 'the top'.
19th hole: I'm sure that this has been posted some years ago but in response to the question by 7trademark a day or two ago about why the share price has fallen from £10, it makes for interest - although not an answer. htTps:// Showing the share price at £10 and a market cap of £648M. On a like for like it 490p or thereabouts is equivalent today. Oh, and plus 4.5 years of continued development!
realist1950: The movement in share price hardy warrants discussion in my opinion. A simple supply / demand dynamic at play.....and all pretty familiar if you've been part of the markets for any length of time. The share price has moved sharply. And now it will cool for a while. The share price will reflect stock availability vs the desire in the market.....both of which fluctuate. A larger holder is releasing some stock at these levels, as we can see. Not in itself a cause for concern, in my opinion, given their history or investment style, plus the fact they have warrants at 100p. Retraces along the way all fully factored in before buying and are purely part and parcel of even the most bullish of stocks, over a period of time. If you prepare yourself well, beforehand, these periods are not in the least bit stressful. Of course one cannot account for everything and as I have posted, several times, it will in all likelihood be a bumpy journey - befitting a small pharma company like this - with a few missed shots I'm sure, but overall the story is compelling and clearly the opportunity to build some strong value is all there to be seen, with a share price that should generally tally, in the fullness of time. To the contributor worrying about their 'spiked' entry. I would ask yourself, what were the reasons for your purchase......and do those reasons still exist or have they been quashed? If your only reason was 'because the share price was going up', then yes, you've been spiked and your reasoning is no longer valid in remaining a holder. As harsh as it sounds, many trader / investors work to such basic logic and wonder why they get caught in a cycle of buying high and selling low. However, if your reasoning was more in depth, and those reasons have not changed since your entry, then you form different answers as to what to do. As I said, make a plan regarding your position......otherwise someone else will make a plan for you......or the share price itself will, which quite often doesn't match the reality within a business. ADYOR as ever and reach your own conclusions. Rgds.
3windy: Directors put in a lot of their own cash, already had the share price up at £10k. They are not going to sell for below its fair price. They will want to get the good news out first and then get a feel for where the share price is at and what offers are on the table. Number one rule in negotiations, always let the other side put their number forward first
realist1950: Over and beyond where we each feel the share price can go, there is a lot to discuss here. For those who believe 4D can 10 or 20 bag over the coming months there are certainly some rational arguments which can be cited in support of such targets. Perhaps one of the strongest is the very fact that we are dealing with a whole new class of drug and the value that can be built from here (ie the floor upwards) as proof of concept and validation grows (both within the company and sector) is certainly significant. Remember, that 4D holds the strongest patent portfolio in the space and, thanks to the acquisitions it made, has a good 20 year backlog of expertise and knowledge on its books. As I have posted before, for a large player wanting immediate and in depth exposure to the space, the company is highly attractive. The inherent safety profile (over other 'traditional' drugs) also promises a swifter route to full commercialisation, which is of course attractive to us all, on every level.....including, lest we forget, patients themselves. We now have some useful benchmark stocks which indicate very clearly how the market can react - both to those pharmas working in the Covid-19 space AND the microbiome space. So....monitoring MCRB's progression here is wholly appropriate. And, to a somewhat lesser extent, SNG too....purely for its work in the Covid-19 space. This company has seen a 2163% increase this year on the back of good work in the lab. As others have noted, we can also see how specific analysts (some of which, 4D share with the above) are willing to seriously upgrade stocks, even on the back of considerable rises (MCRB touched up 600% a few sessions ago, followed by terrific strength since). For 4D (and most pharmas) it will ultimately come down to advances and success in the clinical trials, and, I suspect further partnering with other quality / blue chip businesses as we move forwards. There is already some spread of risk here due to the number of trials the company is running and for varying indications using different candidates. There are 3 or more near term "shots on goal". I am cautious and I do not necessarily expect all three or four to be converted, but the good news is (and as we've seen elsewhere) any SINGULAR success would be hugely significant - both for the space, for the company and for science more broadly. THAT is what is so compelling - the fact that we are amongst a few front-runners, opening up the very space. The results and information to date are encouraging and it will be interesting to see which trial we are updated on next. As counterintuitive as it might seem, I actually feel more confident about success in the Oncology study than the others - yes, perhaps the hardest and most challenging disease to treat. But interest and excitement within the company about the early results from this trial is palpable. The damping of the inflammation in the lung for Covid-19 patients - as shown in severe Asthma patients (and the potential to prevent admission to into intensive care) I think will also come good. Blautix for IBS - we will find out soon enough, I'm sure. But success in any one will go a very long way to derisking the company. I expect to reassess towards the end of the year when data from Oncology begins to flow. It will be very interesting to see what price the company is trading at come that time.....AND how flat my hands will have become, for all the sitting on them. If the story remains intact and positive data begins to emerge, sometimes the best thing is to do nothing. Certainly, the progression of SNG's share price has been outstanding.
monkeywench1: El Rampo I honestly don't know where to start with you! Lets start with your last comment posted at me. `Monkey, you have never applied to the guild and it is stated quite clearly all are welcome. There are caveats once inside, which I feel you would be the first to be expelled. It was set as a haven because of immature people like you that sought to disrupt debate. Your double standards seems to be the norm. We endured several years of your one-line jibes - It wasn't until the predicted crash of your beloved IQE did you exit stage left with your tail between your legs.` You say ` Could it be I am capable of critical thinking!` One definition of critical thinking is ` the objective analysis and evaluation of an issue in order to form a judgement.` However your idea of critical thinking is to create an echo chamber ( I call it a playground ) where any dissenting views are dealt with by expulsion!! You say ` all are welcome ` to the playground. However anyone who has an alternate view is deemed immature. Call me immature for calling your guild a playground by all means, but that is what it is. Playground definition - A playground is a place specifically designed to enable children to play there. You say ` We endured several years of your one-line jibes` Unfortunately for you, I will not be bullied by yourself or your followers. I only posted because of the ramping of opti to newbies at £1.25 which is immoral and unethical. I offered the alternate view which you try and close down by going to your private playground. Hopefully not too many were caught on that spike. For the record you have posted 2790 times on the `someuwin` opti thread - all designed to support the share price to protect your investment.(You failed btw ) I posted a mere!! 1124 times in order to protect the wealth of others who do not possess your amazing ` critical thinking ` skills. ( For the record I have posted 24 times on IQE boards ).Your private playground has had 9091 posts...many from yourself and as we know, only one side of the investment case is allowed. You have also set up an online blog to protect your investment where you unbelievably beg for money. Shame on you, but I suppose you have to recoup your losses somehow. You say ` It wasn't until the predicted crash of your beloved IQE did you exit stage left with your tail between your legs.` Thank you for reminding me of one of my most valuable experiences on the market. It seems I am reasonably good at timing my buys, however knowing when to sell is an art I have not perfected. Although I made a very good return on IQE it could have been much more!I imagine you know what that feels like having seen £1.25 come and go with opti. As a critical thinker I know you are aware of opportunity cost. I have reinvested my profits from IQE and my portfolio continues to grow. Its been 2 years now since opti hit £1.25. Now 53p on the bid. Finally ( for now ) You say ` I dare you to copy paste a single tantrum you speak of from me! Definition of tantrum `an uncontrolled outburst of anger and frustration, typically in a young child. "he has temper tantrums if he can't get his own way".` You really cannot make this up. Lets forget this `Ferdi, please explain why I am the "most dangerous breed of poster on these boards!" It's utterly pathetic, you must realise or are you so fragile!!` Elrampo has a large investment in a stock. The value of the stock is decreasing daily and he is quite understandably worried. Rather than listen to both sides of the investment case, he tries to justify his investment and becomes emotionally attached and falls in love with the share. He must do all he can to shore up the share price He becomes ` friendly` with the CEO and allows himself to become the his mouthpiece and acts like he may have important information. Of course all the price sensitive information must be RNS`d. This does not deter El Rampo. He is in love. Besotted. No-one can criticise his beloved OPTI. The CEO suggests a divi in the form of shares will be distributed to shareholders. Did I miss that?? We are told by El Rampo on 9th April 2020 that opti does not need cash. It must be true because El Rampo the critical thinker tells us so. Anyone who disagrees is immature, a troll, childish yadda yadda yadda. ( Hat tip to TW ). Then on 17th April 2020 OPTI has a placing and raises £1m. Hmmmm. So El Rampo - you are one massive temper tantrum. You cannot get your own way so in an outburst of anger and frustration you create a private playground where you are the playground bully and control the other childrens behaviour. I am tempted to say ` grow up`, I am tempted to suggest you may have a narcissistic personality disorder, however I just think you need to have a good look in the mirror, think about the puerile comments you make to others who disagree with you and think about how you can amend your behaviours to become a better person.
hodr: Have a read of the 'Notes to the Financial Information', cash sorted till end of Q4 and many significant opportunities before then! Don't worry. When I have talked to CEO's of FTSE 250 company's in the past they are not bothered about the share price and short term movements. They are focused on the fundamentals of the business and material value adding events, as the share price will look after itself. Their eyes are on the outcomes and making sure they happen, not checking share price every hour, even if they have £50m worth of shares. "The Directors have prepared detailed financial forecasts and cash flows looking beyond twelve months from the date of the approval of   these financial statements. In developing these forecasts, the Directors have made assumptions based upon their view of the current and future economic conditions that are expected to prevail over the forecast period. Shortly after the year end the Group issued and placed new ordinary shares to raise combined gross proceeds of £22 million from the issue of new share capital. Together with restructuring measures undertaken in light of COVID-19 the Directors estimate that the cash held by the Group together with known receivables will be sufficient to support the current level of activities to the end of quarter four of 2020. The Directors are continuing to explore sources of finance available to the Group and have a reasonable expectation that they will be able to secure sufficient cash inflows into the Group to continue its activities for not less than twelve months from the date of approval of these accounts. They have therefore prepared the financial statements on a going concern basis."
marketanalyst1: Howard Stanley Marks, the billionaire serial investor and founder of Oaktree Capital Management, once opined that: "When looking for the best stocks to buy, it pays to follow the money.” Indeed, investing alongside some of the world’s wealthiest can be very profitable. Take 4D Pharma for example; the London-listed pharmaceutical company (specialising in the development of live biotherapeutic products) currently boasts City heavyweight Richard Griffiths as its largest shareholder. The extremely well-heeled (estimated net worth of circa £300m) serial investor, who carved out a hugely successful business advising small and medium-sized companies, owns close to 14% of the company and is one of the most highly regarded investors in the UK. Known for his innate ability to unearth mispriced opportunities, Mr Griffiths is one of those high-net-worth investors who prefer to keep things pretty simple; invest in well-run companies, with significant growth potential, and that sport a substantial discount to NAV. Pretty simple. Thus, cue 4D Pharma. The Leeds-based pharmaceutical company, currently spearheading a revolutionary new class of medicines called Live Biotherapeutics, has four, advanced, clinical-stage programmes underway in immuno-oncology, IBS, asthma and IBD. However, there’s a problem. The recent stock market rout has given rise to a staggering, and wholly unwarranted, share price dislocation that, frankly, beggars belief. Here’s why; • On January 10, 2020, 4D Pharma had zero debt. • On January 10, 2020, 4D Pharma had cash and cash equivalents of circa £3.5 million (down from £12.9m at July 01, 2019). • On February 18, 2020, 4D Pharma raised gross proceeds of £22m at 50p per share. • On March 01, 2020, 4D Pharma had cash and cash equivalents of circa £23.5 million. • By March 18, 2020, 4D Pharma’s BOD had garnered some serious ‘skin in the game’; all three directors collectively owned 22% (24,091,936 shares) of the company! • On March 18, 2020, 4D Pharma delivered the FIRST global clinical confirmation of a live biotherapeutic product initiating a response in cancer patients; evidence of tumour shrinkage and no drug-related adverse events were observed. Overall, 51% reduction in target tumours was observed. • The company’s first significant readout (Blautix® Phase II interim analysis), which is likely to trigger a material share price re-rate, is expected within three weeks’ time (April – early Q2 2020). • The company’s second significant readout (MRx0518 Phase I/II combination study with Keytruda®), which is also likely to trigger a material share price re-rate, is expected within seven weeks’ time (around May 2020). So, with a current market cap of £26.5m (26p), and less cash of £23.5m, means the market is valuing the company’s incredibly advanced and highly promising stable of drug candidates at £3.5m! Yes, feel free to bark the unsavoury but apt remark, “What the ….!” And yes, the stock market is not always the perfect arbiter of value. However, for as sure as night follows day, the market will soon move to correct the gross mispricing. In the meantime, the recently-released clinical data for the company’s lead oncology candidate may help to explain why Griffiths, the BOD, Invesco, and Henderson continue to clutch onto their 14%, 22%, 8.5%, and 3% stakes respectively.
4d Pharma share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
4d Pharma
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201001 23:57:16